Precision Optics Corporation, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal 2022. Although the request metadata says “2022 Q4,” this filing reports the full fiscal year ended June 30, 2023, not a standalone quarter.
Business context
Precision Optics designs, develops, manufactures and sells optical components, assemblies, medical visualization products and related engineering services. Its business includes medical applications and defense, aerospace and industrial customers. In FY2023, optical components generated about 50% of business, engineering services 32%, and medical device assemblies 18%. Revenue growth was led by large defense and aerospace component orders.
Financial results and liquidity
| Metric | FY2023 / June 30, 2023 | FY2022 / June 30, 2022 |
|---|---|---|
| Revenue | $21.04 million | $15.68 million |
| Gross profit / gross margin | $7.73 million / 36.8% | $4.93 million / 31.4% |
| Operating loss | $(638,548) | $(1.51) million |
| Net loss | $(144,613); $(0.03) per share | $(928,416); $(0.18) per share |
| Operating cash flow | $(81,090) | $(933,371) |
| Cash and cash equivalents | $2.93 million | $605,749 |
| Current assets / current liabilities | $9.86 million / $5.26 million | $6.51 million / $4.59 million |
| Long-term debt, including current maturities | $2.69 million | $2.33 million |
Revenue increased 34.2%. Gross profit rose 56.9%, with management citing higher revenue, improved resource utilization and a one-time $600,000 sale of technology rights. Gross margin excluding that sale would be approximately 33.9%, based on the figures disclosed. Operating expenses increased; the company continued to report operating and net losses. Net loss improved partly because of a $714,798 gain from revaluing the Lighthouse acquisition earn-out liability, which was not a cash operating gain.
Cash increased primarily through financing: a June 2023 stock placement generated approximately $2.29 million in reported net proceeds, and the company borrowed $750,000 under a new term loan. The $1.25 million revolving credit facility had no balance outstanding at year-end. Current liabilities included $1.17 million of customer advances. The company reported $1.98 million of open purchase-order commitments and future lease payments; these are additional cash obligations to monitor.
Changes, outlook and notable matters
- Optical component revenue increased about $4.04 million and engineering revenue about $1.36 million year over year; assembly production revenue was virtually unchanged.
- Receivables rose to $3.91 million, and the doubtful-account allowance increased to $606,715 from $44,135, primarily to cover potential loss from an insolvent customer. Two customers each represented more than 10% of year-end receivables.
- The Lighthouse earn-out was not payable because the required gross-profit targets were not met; the remaining liability was written off, producing a reported gain. The Ross Optical earn-out was fully paid.
- Management said it expected the customer project pipeline to expand as development projects move into production, and described the engineering pipeline as strong. It did not provide quantified revenue, earnings or cash-flow guidance and stated it had no material trends or uncertainties to report.
- Disclosure controls and internal control over financial reporting were deemed ineffective at June 30, 2023 due to a material weakness. The auditor issued an unqualified opinion on the financial statements but was not engaged to audit internal controls.
- Key business risks described include competition from larger, better-resourced companies; dependence on a limited number of suppliers for certain optical glass and CMOS sensors; customer credit exposure; and regulatory requirements for medical and defense-related products. The primary Gardner facility is leased month-to-month from a related party; management described the facilities as adequate for current operations.
Most important facts to verify
- Reconcile the MD&A expense figures with the audited statements: MD&A cites R&D of $809,877 and SG&A of $7,740,562, while the statements report $992,375 and $7,380,309, respectively.
- Review the material weakness, its cause and any remediation plan or subsequent update; the filing reports no material control changes during FY2023.
- Assess collectability of receivables, especially the exposure to the insolvent customer and the two customers exceeding 10% of receivables.
- Evaluate whether recurring operations can generate positive cash flow without additional borrowing or equity issuance, given the operating loss and negative operating cash flow.
- Confirm the effect of the $600,000 technology-rights sale and the earn-out revaluation on recurring profitability; check the filing’s detailed financial statements and notes for the underlying accounting.